Trade LENSAR, Inc. - LNSR CFD

Add to favourite

3.00

1.32%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.19

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

LENSAR Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	3.04
Open*	3
1-Year Change*	12.36%
Day's Range*	2.98 - 3.29
52 wk Range	1.80-4.80
Average Volume (10 days)	42.95K
Average Volume (3 months)	606.89K
Market Cap	43.76M
P/E Ratio	-100.00K
Shares Outstanding	11.25M
Revenue	40.29M
EPS	-1.23
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Mar 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	3.00	0.00	0.00%	3.00	3.29	2.98
Apr 17, 2024	3.04	0.04	1.33%	3.00	3.13	2.98
Apr 16, 2024	3.00	-0.08	-2.60%	3.08	3.08	2.95
Apr 15, 2024	3.13	-0.15	-4.57%	3.28	3.28	3.08
Apr 12, 2024	3.16	0.17	5.69%	2.99	3.19	2.98
Apr 11, 2024	3.08	0.09	3.01%	2.99	3.18	2.99
Apr 10, 2024	2.99	-0.17	-5.38%	3.16	3.24	2.98
Apr 9, 2024	3.19	0.07	2.24%	3.12	3.30	3.12
Apr 8, 2024	3.18	0.12	3.92%	3.06	3.22	2.67
Apr 5, 2024	2.99	0.01	0.34%	2.98	3.16	2.83
Apr 4, 2024	3.16	-0.15	-4.53%	3.31	3.37	3.11
Apr 3, 2024	3.30	-0.01	-0.30%	3.31	3.39	3.23
Apr 2, 2024	3.30	-0.10	-2.94%	3.40	3.49	3.30
Apr 1, 2024	3.36	-0.02	-0.59%	3.38	3.45	3.24
Mar 28, 2024	3.37	-0.11	-3.16%	3.48	3.58	3.37
Mar 27, 2024	3.63	0.26	7.72%	3.37	3.72	3.37
Mar 26, 2024	3.48	0.09	2.65%	3.39	3.55	3.39
Mar 25, 2024	3.39	-0.11	-3.14%	3.50	3.51	3.03
Mar 22, 2024	3.42	-0.17	-4.74%	3.59	3.72	3.31
Mar 21, 2024	3.57	-0.30	-7.75%	3.87	4.02	3.48

LENSAR, Inc. Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 15:00	Country US	Event LENSAR Inc Annual Shareholders Meeting LENSAR Inc Annual Shareholders Meeting Forecast - Previous -
Monday, May 13, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 LENSAR Inc Earnings Release Q1 2024 LENSAR Inc Earnings Release Forecast - Previous -
Friday, May 24, 2024
Time (UTC) 14:00	Country US	Event LENSAR Inc Annual Shareholders Meeting LENSAR Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 LENSAR Inc Earnings Release Q2 2024 LENSAR Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	35.358	34.459	26.382	30.528	24.388
Revenue	35.358	34.459	26.382	30.528	24.388
Cost of Revenue, Total	15.403	16.626	12.307	17.299	13.64
Gross Profit	19.955	17.833	14.075	13.229	10.748
Total Operating Expense	55.535	54.111	44.884	43.242	33.704
Selling/General/Admin. Expenses, Total	27.17	23.887	23.768	17.147	16.143
Research & Development	11.814	12.358	7.553	7.569	2.784
Depreciation / Amortization	1.148	1.24	1.256	1.227	1.137
Operating Income	-20.177	-19.652	-18.502	-12.714	-9.316
Interest Income (Expense), Net Non-Operating	0.263	0.051	-1.286	-2.001	-3.321
Other, Net			0.014	0.058	0.064
Net Income Before Taxes	-19.914	-19.601	-19.774	-14.657	-12.573
Net Income After Taxes	-19.914	-19.601	-19.774	-14.657	-12.593
Net Income Before Extra. Items	-19.914	-19.601	-19.774	-14.657	-12.593
Net Income	-19.914	-19.601	-19.774	-14.657	-12.593
Total Adjustments to Net Income				0	-1.451
Income Available to Common Excl. Extra. Items	-19.914	-19.601	-19.774	-14.657	-14.044
Income Available to Common Incl. Extra. Items	-19.914	-19.601	-19.774	-14.657	-14.044
Diluted Net Income	-19.914	-19.601	-19.774	-14.657	-14.044
Diluted Weighted Average Shares	10.159	9.374	4.621	10.6346	10.6346
Diluted EPS Excluding Extraordinary Items	-1.96023	-2.091	-4.27916	-1.37824	-1.3206
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-1.96023	-2.091	-4.27916	-1.37824	-1.3206

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	12.012	8.252	10.232	7.748	8.038
Revenue	12.012	8.252	10.232	7.748	8.038
Cost of Revenue, Total	5.251	3.932	3.75	3.859	3.146
Gross Profit	6.761	4.32	6.482	3.889	4.892
Total Operating Expense	14.879	12.613	12.845	11.831	14.836
Selling/General/Admin. Expenses, Total	7.854	6.755	7.204	6.119	7.569
Research & Development	1.499	1.65	1.615	1.577	3.834
Depreciation / Amortization	0.275	0.276	0.276	0.276	0.287
Operating Income	-2.867	-4.361	-2.613	-4.083	-6.798
Interest Income (Expense), Net Non-Operating	0.111	0.089	0.123	0.092	0.039
Net Income Before Taxes	-8.753	-4.272	-2.49	-3.991	-6.759
Net Income After Taxes	-8.753	-4.272	-2.49	-3.991	-6.759
Net Income Before Extra. Items	-8.753	-4.272	-2.49	-3.991	-6.759
Net Income	-8.753	-4.272	-2.49	-3.991	-6.759
Income Available to Common Excl. Extra. Items	-8.753	-4.272	-2.49	-3.991	-6.759
Income Available to Common Incl. Extra. Items	-8.753	-4.272	-2.49	-3.991	-6.759
Diluted Net Income	-8.753	-4.272	-2.49	-3.991	-6.759
Diluted Weighted Average Shares	10.82	10.716	10.369	10.225	10.073
Diluted EPS Excluding Extraordinary Items	-0.80896	-0.39866	-0.24014	-0.39032	-0.671
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.80896	-0.39866	-0.24014	-0.39032	-0.671
Other, Net	-5.997

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	33.716	44.813	58.385	17.183	11.747
Cash and Short Term Investments	14.674	31.637	40.599	4.615	3.344
Cash			40.599	4.615	3.344
Total Receivables, Net	6.24	4.988	2.456	3.886	3.774
Accounts Receivable - Trade, Net	6.04	4.638	2.012	3.384	3.302
Total Inventory	11.74	6.488	13.473	8.064	4.062
Prepaid Expenses	1.062	1.7	1.857	0.618	0.567
Total Assets	55.844	66.465	79.12	34.536	28.885
Property/Plant/Equipment, Total - Net	9.509	10.597	8.083	3.004	3.616
Property/Plant/Equipment, Total - Gross	20.203	19.34	15.719	9.865	8.365
Accumulated Depreciation, Total	-10.694	-8.743	-7.636	-6.861	-4.749
Intangibles, Net	12.122	10.87	12.11	13.366	12.293
Note Receivable - Long Term	0.442	0.121	0.452	0.827	0.753
Other Long Term Assets, Total	0.055	0.064	0.09	0.156	0.476
Total Current Liabilities	11.421	8.714	8.467	7.829	7.66
Accounts Payable	5.422	2.694	2.481	1.577	1.412
Accrued Expenses	5.231	5.116	5.063	5.333	3.623
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.768	0.904	0.923	0.919	2.625
Total Liabilities	13.86	11.586	11.91	65.089	49.35
Total Long Term Debt	0	0	0	56.617	41.211
Long Term Debt			0	56.617	41.211
Other Liabilities, Total	2.439	2.872	3.443	0.643	0.479
Total Equity	41.984	54.879	67.21	-30.553	-20.465
Common Stock	0.111	0.11	0.109	0.096	0.096
Additional Paid-In Capital	139.381	132.363	125.094	7.536	2.967
Retained Earnings (Accumulated Deficit)	-97.508	-77.594	-57.993	-38.185	-23.528
Total Liabilities & Shareholders’ Equity	55.844	66.465	79.12	34.536	28.885
Total Common Shares Outstanding	11.102	10.99	10.933	10.6346	10.6346
Cash & Equivalents	14.674	31.637

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	48.645	49.164	29.975	33.716	32.171
Cash and Short Term Investments	24.92	25.466	7.97	14.674	19.293
Cash & Equivalents	24.92	25.466	7.97	14.674	19.293
Total Receivables, Net	5	4.643	5.267	6.24	3.686
Accounts Receivable - Trade, Net	4.736	4.048	5.064	6.04	3.56
Total Inventory	17.481	18.152	15.668	11.74	7.89
Prepaid Expenses	1.244	0.903	1.07	1.062	1.302
Total Assets	70.853	71.196	51.961	55.844	54.801
Property/Plant/Equipment, Total - Net	7.438	6.764	6.768	6.879	7.371
Intangibles, Net	11.298	11.571	11.845	12.122	12.398
Note Receivable - Long Term	1.131	1.221	0.768	0.442	0
Other Long Term Assets, Total	2.341	2.476	2.605	2.685	2.861
Total Current Liabilities	11.011	10.556	9.992	11.421	9.788
Accounts Payable	3.936	4.619	4.923	5.422	3.506
Accrued Expenses	6.011	4.87	4.037	5.231	5.474
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	1.064	1.067	1.032	0.768	0.808
Total Liabilities	20.723	24.759	12.523	13.86	12.218
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	9.712	14.203	2.531	2.439	2.43
Total Equity	50.13	46.437	39.438	41.984	42.583
Common Stock	0.112	0.112	0.111	0.111	0.11
Additional Paid-In Capital	144.236	143.111	141.107	139.381	137.491
Retained Earnings (Accumulated Deficit)	-107.965	-110.533	-101.78	-97.508	-95.018
Total Liabilities & Shareholders’ Equity	70.853	71.196	51.961	55.844	54.801
Total Common Shares Outstanding	11.246	11.199	11.103	11.102	11.023
Redeemable Preferred Stock	13.747	13.747

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-19.914	-19.601	-19.774	-14.657	-12.593
Cash From Operating Activities	-14.856	-8.969	-13.791	-12.589	-1.885
Cash From Operating Activities	2.258	1.524	1.309	2.639	3.453
Amortization	1.148	1.24	1.256	1.227	1.137
Non-Cash Items	7.229	7.91	9.607	0.561	0.197
Cash Taxes Paid	0.003	0.019		0	0
Cash Interest Paid	0	0	0.478	0.473	0.272
Changes in Working Capital	-5.577	-0.042	-6.189	-2.359	5.921
Cash From Investing Activities	-0.115	-0.354	-0.326	-2.089	-3.892
Capital Expenditures	-0.115	-0.354	-0.366	-2.089	-3.892
Cash From Financing Activities	-1.992	0.361	50.001	15.949	6.955
Financing Cash Flow Items	-2.4			-1.071	-0.214
Issuance (Retirement) of Stock, Net	0.408	0.361	37.601	3.795	3.669
Issuance (Retirement) of Debt, Net		0	12.4	13.225	3.5
Net Change in Cash	-16.963	-8.962	35.884	1.271	1.178
Other Investing Cash Flow Items, Total		0	0.04

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-4.272	-19.914	-17.424	-13.433	-6.674
Cash From Operating Activities	-6.696	-14.856	-10.098	-5.397	-2.607
Cash From Operating Activities	0.578	2.258	1.681	1.11	0.541
Amortization	0.276	1.148	0.872	0.596	0.309
Non-Cash Items	1.853	7.229	5.491	3.629	1.871
Cash Interest Paid	0.001	0	0	0	0
Changes in Working Capital	-5.131	-5.577	-0.718	2.701	1.346
Cash From Investing Activities	-0.008	-0.115	-0.058	-0.056	-0.046
Capital Expenditures	-0.008	-0.115	-0.058	-0.056	-0.046
Cash From Financing Activities		-1.992	-2.188	-0.988
Issuance (Retirement) of Debt, Net
Net Change in Cash	-6.704	-16.963	-12.344	-6.441	-2.653
Cash Taxes Paid		0.003	0.01	0.01
Other Investing Cash Flow Items, Total
Issuance (Retirement) of Stock, Net		0.408	0.212	0.212
Financing Cash Flow Items		-2.4	-2.4	-1.2

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

LENSAR, Inc. Company profile

About LENSAR Inc

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. It is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, LENSAR Inc revenues increased 31% to $34.5M. Net loss decreased 1% to $19.6M. Revenues reflect Europe segment increase of 62% to $5.8M, South Korea segment increase of 42% to $4.4M. Lower net loss reflects Stock-based Compensation in SGA decrease of 21% to $5.9M (expense), Interest expense decrease from $1.3M (expense) to $0K.

Industry:

Advanced Medical Equipment & Technology (NEC)

2800 Discovery Drive
Suite 100
ORLANDO
FLORIDA 32826
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024